Harten Group

Search form

Pharmaceutical Consulting

You may need a medical expert report, regulatory document, product acquisition assessment or risk benefit analysis turned around within a tight timescale. Perhaps you want a market entry assessment or Due Diligence carried out by an independent expert? Or are you anticipating a GCP inspection and are concerned that you may not be adequately prepared?

To meet all of these requirements - and many others - Harten Group has over 2000 specialist consultants with experience in a wide range of disciplines at your disposal. Our technical consultants can work with you, individually or in small teams, when you want them, delivering a first-class professional service. This is achieved through knowing and working with our consultants over ten years, choosing the optimum skill set and experience for each individual project.

Simply call us to discuss your project needs, and within 48 hours, we can provide you with impartial, informed advice on both the feasibility of your request and our ability to help. We aim to provide an estimate of project costs and a proposal within five to seven working days.

What we found most impressive about our recent assignment for which Harten Group provided a team of consultants was the ongoing attention to detail. Throughout the project – three months – we received regular calls to find out how things were progressing and a face to face meeting to ensure that both parties were happy.

HR Manager, Pharma Company

Latest assignments

Phase I/II Physician

6 months, likely to extend

Medical Director / Clinical Science Director

6 months, likely to extend

Interim Medical Director

6 months, likely to extend

Recent projects & updates

A consultant has been helping a generics company headquartered in Ireland, currently branching into branded pharmaceuticals, with training and raising awareness of the Code to ensure local and UK compliance.

Harten Group consultant handles all regulatory requirements for compiling and submitting monthly safety updates for a global pharma company's antiviral during flu epidemic.

Read full details >>